Tuesday, September 15, 2020

MRNS Catches Eye, SAVA Soars On Alzheimer's Study, ETNB Abuzz Over NASH Trial, GILD Snaps Up IMMU

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

from RTT - Biotech https://ift.tt/3mk0SPj
via IFTTT

No comments:

Post a Comment